RxDoctor Payments Data

Livina Akpunku, NP

Psychiatric/Mental Health · Corpus Christi, TXNPI 1700254646

Payments from drug & device makers

$2,982in general payments, 2019–2025

Across 34 payments — averaging $87.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$490
  • Teva Pharmaceuticals USA, Inc.$236
  • Corcept Therapeutics$229
  • Neurocrine Biosciences, Inc.$227
  • Nevro Corp.$217
  • Acadia Pharmaceuticals Inc$215
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$2,87096%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,982 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$144,834
Medicare patients
229
Services billed
2,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$15,162
Buspirone Hcl290$5,715
Divalproex Sodium173$4,556
Memantine Hcl158$4,430
Sertraline Hcl262$2,503
Trazodone Hcl235$2,313
Donepezil Hcl197$2,249
Duloxetine Hcl139$2,185
Clonazepam52$1,854
Paroxetine Hcl143$1,710
Citalopram HbrCitalopram Hydrobromide185$1,576
Escitalopram Oxalate155$1,558
Temazepam15$1,294
Quetiapine Fumarate60$827
Oxcarbazepine28$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$185$15,16221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →